One important detail that shouldn’t be forgotten is that the Reata suitors’ interest was primarily in the global rights to an already FDA-approved rare disease drug. In Neuren’s case, the global rights for trofinetide have already been licensed to Acadia.
While the NNZ-2591 pipeline is potentially worth more than that of trofinetide, it is yet to see successful results in Phase 2, yet alone FDA approval.
The question is, if NNZ-2591 comes up trumps in Phase 2, is there a party prepared to come in hard and fast, knocking out potential competitors with a killer offer, despite needing to take on Phase 3 costs as well as development and regulatory risk?
One important detail that shouldn’t be forgotten is that the...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.31 |
Change
-0.790(3.93%) |
Mkt cap ! $2.465B | |||
| Open | High | Low | Value | Volume |
| $19.86 | $19.99 | $17.97 | $22.67M | 1.196M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2222 | $19.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.31 | 8162 | 3 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.25 |
Change
-0.790 ( 4.18 %) |
||||
| Open | High | Low | Volume | ||
| $19.88 | $19.88 | $17.97 | 249066 | ||
| Last updated 15.59pm 09/05/2024 ? | |||||
| NEU (ASX) Chart |